Page last updated: 2024-12-06
mopidralazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71143 |
| CHEMBL ID | 275739 |
| SCHEMBL ID | 2109925 |
| MeSH ID | M0116632 |
Synonyms (21)
| Synonym |
|---|
| 75841-82-6 |
| mopidralazine |
| mdl-899 |
| mopidralazine [inn] |
| CHEMBL275739 |
| n-(2,5-dimethylpyrrol-1-yl)-6-morpholin-4-ylpyridazin-3-amine |
| mopidralazinum |
| mopidralazina |
| 3-pyridazinamine, n-(2,5-dimethyl-1h-pyrrol-1-yl)-6-(4-morpholinyl)-, monohydrochloride |
| 4-(6-((2,5-dimethylpyrrol-1-yl)amino)-3-pyridazinyl)morpholine |
| mopidralazinum [latin] |
| 96600s6glk , |
| mopidralazina [spanish] |
| unii-96600s6glk |
| mopidralazine [mart.] |
| n-(2,5-dimethyl-1h-pyrrol-yl)-6-morpholino-3-pyridazineamine |
| JBVCSNJKVNKDHK-UHFFFAOYSA-N |
| n-(2,5-dimethyl-1h-pyrrol-1-yl)-6-morpholino-3-pyridazineamine |
| SCHEMBL2109925 |
| Q27271872 |
| DTXSID60868380 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "We conducted pharmacodynamic studies with a new vasodilator, MDL-899." | ( Pharmacodynamic studies in normal volunteers with MDL-899, a new arteriolar vasodilator. Elliott, HL; Howden, CW; Lawrie, CB; Reid, JL, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.80) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||